Odyssey Health, Inc. announced that it has filed for United States and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device. As announced, Odyssey's recently completed Phase I study to treat concussion successfully used Odyssey's Nasal Device and drug combination. Odyssey designed the Nasal Device with a novel drug dispensing system that creates an effective airflow for depositing concentrated drug deep into the nasal cavity and onto the olfactory region for quick and direct diffusion into the brain to treat central nervous system injury, disease or disorder.

The Phase I study used Odyssey's novel Nasal Device to deliver Odyssey's concussion drug, PRV-002, and to determine the safety of its PRV-002 concussion drug. The PRV-002 concussion drug-Nasal Device combination was well-tolerated in 40 healthy human volunteers. The study documented no Nasal Device failures.